Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the ...
The BMJ

Long term benefits of blood pressure lowering . . . and other research

Tom Nolan reviews this week’s research Critics argue that limited dosing options for polypills mean patients get suboptimal ...
The Manila Times

Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European ...

Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE)-- Beam Therapeutics Inc. (Nasdaq: BEAM), ...
TCTMD

Quantifying Inflammation Can Add to CV Risk Prediction Even in No-Contrast Scans

Experts hope the FAI score can become the next big tool in personalized risk assessment, though costs remain unknown.
MedPage Today

Singing for Chronic Belching; Excess Cancers in Crohn's; Dual Agonist for Liver Fat

A glucagon and GLP-1 receptor dual agonist showed promise for reducing liver fat in a phase II study of patients with metabolic dysfunction-associated steatotic liver disease and steatohepatitis. ( ...